Loading...
•
Sep 30, 2021
PTC Therapeutics Q3 2021 Earnings Report
PTC Therapeutics reported a total quarterly revenue of $139 million, a 17% increase year-over-year, and raised its 2021 DMD franchise revenue guidance.
Key Takeaways
PTC Therapeutics announced its Q3 2021 financial results, with total revenues of $138.7 million, a 17% increase compared to Q3 2020. The company also raised its 2021 DMD franchise revenue guidance to $400-$420 million. APHENITY Phase 3 trial of PTC923 in phenylketonuria (PKU) was initiated.
DMD franchise grew 39% over Q3 2020, with net product revenue of $114 million.
Translarna revenue growth was driven by geographic expansion and new patient identification.
Emflaza revenue growth was driven primarily by new patient starts and maintained high compliance.
Evrysdi's first commercial sale in Japan triggered a $10 million milestone payment from Roche.
PTC Therapeutics
PTC Therapeutics
PTC Therapeutics Revenue by Segment
Revenue by Segment
Translarna Revenue
CapyFin.comEmflaza Revenue
CapyFin.comDMD Franchise Revenue
CapyFin.com Forward Guidance
PTC updated its full year 2021 guidance, anticipating net product revenues for the DMD franchise to be between $400 and $420 million and GAAP R&D and SG&A expense to be between $815 and $835 million.
Positive Outlook
- Net product revenues for the DMD franchise for the full year 2021 to be between $400 and $420 million.
- GAAP R&D and SG&A expense for the full year 2021 to be between $815 and $835 million.
- Non-GAAP R&D and SG&A expense for the full year 2021 to be between $715 and $735 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income